Build Canada LogoBuilder MP
← Back to bills

National Framework on Sickle Cell Disease Act

An Act respecting a national framework on sickle cell disease

Summary

  • Requires the Minister of Health to create a national framework on sickle cell disease within one year, with consultations and a report to Parliament.
  • Establishes clinician training, evidence-based national care standards, a research network, improved data collection, and a national registry.
  • Institutes universal newborn screening and postnatal diagnosis as needed, plus public awareness campaigns and measures to diversify and expand blood donation.
  • Calls for analysis of a targeted tax credit for patients and caregivers, ensures eligibility for existing disability benefits, and examines inclusion of essential treatments in public drug insurance plans.
  • Mandates a follow-up report within three years detailing implementation, effectiveness, outstanding measures, and timelines.

Builder Assessment

Vote No

Overall, the bill is primarily a targeted health framework with limited, indirect ties to national growth, exports, or broad productivity gains. While it may support research and improve care efficiency, it is incremental and could increase public costs without clear economy-wide benefits.

  • It does not directly advance core growth levers (productivity, exports, tax competitiveness) and focuses on a narrow health area.
  • Potential expansions of benefits and drug coverage may raise costs; efficiency gains are plausible but unproven in the bill.
  • To better align: tie the research network to commercialization pathways, measurable cost-savings/ROI targets, and open, de-identified data access for innovators.
  • Leverage existing institutions (CIHR, Canadian Blood Services) to avoid duplicative bureaucracy and set explicit efficiency metrics (e.g., reduced ER visits, fewer hospital days).
  • Use competitive public–private partnerships and outcome-based procurement to develop Canadian-made diagnostics/therapies and scale export potential.
  • Prefer time-limited pilots with sunset/review clauses before committing to broad drug coverage; target any tax credit to support workforce attachment and caregiver labour participation.

Question Period Cards

No question period cards yet.

Principles Analysis

—

Canada should aim to be the world's most prosperous country.

Improves health outcomes for a specific population, with limited direct impact on overall national wealth creation.

—

Promote economic freedom, ambition, and breaking from bureaucratic inertia (reduce red tape).

Creates a coordinated federal framework and standards but does not reduce regulation or materially expand economic freedoms.

—

Drive national productivity and global competitiveness.

May improve productivity for affected individuals and caregivers, but the macroeconomic effect is modest and indirect.

—

Grow exports of Canadian products and resources.

No direct export measures; any export gains would be indirect (e.g., downstream health research outputs).

✓

Encourage investment, innovation, and resource development.

A national research network and registry can catalyze clinical research and potential biotech innovation.

—

Deliver better public services at lower cost (government efficiency).

Standardization and early screening could lower long-run costs, but expanded benefits and potential drug coverage may increase spending; net fiscal impact is unclear.

—

Reform taxes to incentivize work, risk-taking, and innovation.

Only contemplates a targeted tax credit for patients/caregivers; no broader pro-growth tax reform.

✗

Focus on large-scale prosperity, not incrementalism.

A disease-specific framework is incremental and unlikely to materially affect national prosperity.

Did we get the builder vote wrong?

Email [email protected]

S-201

PartySenate
StatusAt second reading in the Senate
Last updatedMay 28, 2025
TopicsHealthcare, Social Issues
Parliament45